Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2149-2158

  Nauck, Michael ^a   Weinstock, Ruth S ^b   Umpierrez, Guillermo E ^c   Guerci, Bruno ^d,e   Skrivanek, Zachary ^f   Milicevic, Zvonko ^f  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITÉ DE LORRAINE   (France)

^e UNIVERSITY HOSPITAL OF NANCY   (France)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PYRAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PANCREATITIS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; STOMACH DISTENSION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT CHANGE; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; RECOMBINANT FUSION PROTEINS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84904992244     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2761     Document Type: Article

References (39)

1. Inzucchi SE, Bergenstal RM, Buse J.B., et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-1379
2. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
3. Holst JJ, Orskov C, Nielsen O.V., Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-174
4. Kreymann B, Williams G, Ghatei M.A., Bloom SR. Glucagon-like peptide-17-36: aphysiological incretin in man. Lancet 1987; 2: 1300-1304
5. Bergenstal RM, Wysham C, Macconell L., et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439
6. Pratley RE, Nauck M, Bailey T., et al; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sita-gliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456
7. Barrington P, Chien JY, Tibaldi F, Showalter H.D., Schneck K., Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab 2011; 13: 434-438
8. Glaesner W, Vick AM, Millican R, et al Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev 2010; 26: 287-296
9. Data onfile, Eli Lilly and Companyand/or one of its subsidiaries
10. Baggio LL, Drucker DJ Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
11. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R, Milicevic Z. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebocontrolled study. Diabet Med 2012; 29: 1260-1267
12. Umpierrez GE, Blevins T, Rosenstock J., Cheng C, Anderson JH, Bastyr EJ 3rdEGO Study Group. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. Diabetes Obes Metab 2011; 13: 418-425
13. Geiger MJ, Skrivanek Z, Gaydos B., Chien J, Berry S, Berry D. An adaptive, dose-finding, seamless phase 2/3 study of a long-acting glucagon-like peptide-1 analog (dulaglutide): trial design and baseline characteristics. J Diabetes Sci Tech 2012; 6: 1319-1327
14. Skrivanek Z, Berry S, Berry D., et al. Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J Diabetes Sci Tech 2012; 6: 1305-1318
15. Spencer K, Colvin K, Braunecker B., et al. Operational challenges and solutions with implementation of an adaptive seamless phase 2/3 study. J Diabetes Sci Tech 2012; 6: 1296-1304
16. World Medical Association. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926
17. Skrivanek ZCJ, Gaydos B, Heathman M., Geiger M, Milicevic Z, Eds. Dose-Finding Results in an Adaptive Trial of Dulaglutide Combined with Metformin in Type 2 Diabetes (AWARD-5). Chicago, IL, American Diabetes Association, 2013
18. Skrivanek Z, Chien JY, Gaydos B, Heathman M., Geiger MJ, Milisevic Z. Dose finding results in an adaptive trial of dulaglutide combined with metformin in type 2 diabetes (AWARD-5). Diabetologia 2013; 56(Suppl. 1): S402
19. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
20. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249
21. Dmitrienko A, Tamhane AC, Wiens BL General multistage gatekeeping procedures. Biom J 2008; 50: 667-677
22. Stratton IM, Adler AI, Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412
23. Zinman B, Gerich J, Buse J.B., et al; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230
24. Nauck M, Frid A, Hermansen K., et al; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90
25. Garber A, Henry R, Ratner R., et al; LEAD-3 (Mono) Study Group. Liraglutide versus glime-piride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481
26. Chapell R, Gould AL, Alexander CM Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab 2009; 11: 1009-1016
27. Pratley RE, Nauck MA, Bailey T, et al; 1860-LIRA-DPP-4 Study Group. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care 2012; 35: 1986-1993
28. DeFronzo RA, Okerson T, Viswanathan P., Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008; 24: 2943-2952
29. Aschner P, Kipnes MS, Lunceford J.K., Sanchez M., Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637
30. Degn KB, Juhl CB, Sturis J, et al One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53: 1187-1194
31. Herman GA, Stevens C, Van Dyck K, et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675-688
32. Fonseca V, McDuffie R, Calles J., et al.; ACCORD Study Group. Determinants of weight gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care 2013; 36: 2162-2168
33. Flint A, Raben A, Astrup A., Holst JJ. Glucagonlike peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520
34. Kieffer TJ, Habener JF The glucagon-like peptides. Endocr Rev 1999; 20: 876-913
35. Drucker DJ, Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705
36. Buse JB, Nauck M, Forst T., et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 2013; 381: 117-124
37. Blevins T, Pullman J, Malloy J., et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310
38. Russell-Jones D. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes. Int J Clin Pract 2010; 64: 1402-1414
39. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 2005; 20(Suppl. 6): vi3-vi9